NCT03753490Active, not recruiting
ABC-Scores for Reduction of Stroke and Mortality in Atrial Fibrillation - The ABC-AF Study
ABC-Risk Scores for Reduction of Stroke and Mortality in Atrial Fibrillation - a Multicenter, Registry-based, Randomized Controlled Parallel-group Open-label Study
Source: ClinicalTrials.gov · Last updated 3 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary study objective is to evaluate if personalized treatment by decision support, based on the biomarker-based risk prediction (ABC-scores) guided strategy, reduces the occurrence of the composite outcome of stroke or death in patients with atrial fibrillation. Approximately 6500 patients will be randomized 1:1 to ABC risk score guided therapy or standard care.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 3933 (estimated)
- First submitted
- 8 Nov 2018
- Start date
- 25 Oct 2018
- Primary completion date
- 31 May 2025
- Lead sponsor
- Uppsala University
- Diseases
- Stroke, Atrial fibrillation
- NCT number
- NCT03753490
What you commit to
- Study type: Interventional
- Planned participants: 3933
- From 25 Oct 2018 to the primary completion date, 31 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently on treatment with a non-vitamin K antagonist oral anticoagulant (NOAC) and not eligible for change of NOAC drug e.g. drug-drug interactions
- Concomitant dual antiplatelet treatment
- Planned for AF ablation or AF surgery
Other illness
- Indication for oral anticoagulant treatment beyond atrial fibrillation, e.g. venous thromboembolism and/or mechanical heart valve prosthesis
- Acute coronary syndrome (myocardial infarction or unstable angina) within the last 30 days
Lab values
- Haemoglobin \<90 g/L
Other
- Contraindication for any oral anticoagulant, according to the SmPC (in Sweden FASS)
- Participation in anti-thrombotic pharmaceutical trial
- Patients who, in the opinion of the investigator, cannot or will not comply with the requirements of the protocol
Who the study is looking for
- Patients with diagnosis of atrial fibrillation, including newly diagnosed, with or without current oral anticoagulant treatment
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Uppsala University Hospital Coordinator of this site? Confirm its status | Uppsala | Sweden | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.